

BioGaia®

Press Release
25 September 2007

BioGaia signs agreement for Turkey

BioGaia has signed an additional agreement with Italchimici SpA in Italy. The agreement gives Italchimici an exclusive right to BioGaia's Probiotic Drops, Tablets and Straw to be marketed in Turkey.

Italchimici, that is marketing BioGaia's drops and tablets in Italy under its own brand since 2005, has entered into a cooperation with Eczacibasi Pharmaceuticals Marketing (EIP), one of the oldest pharmaceutical companies in Turkey, whose parent recently sold its generic business to Zentiva. The cooperation between Italchimici and EIP involves a range of products including BioGaia's probiotic drops, tablets and straws and was facilitated by Bosfor Bioscience Partners, the pharmaceutical Business Development consultancy located in Istanbul. The products will be sold under BioGaia's own brand and the registration process will start immediately. Launch is expected during 2008.

"With this agreement we strengthen and build on the excellent relationship we have with our Italian partners that has made BioGaia's products among the top ten selling probiotics in Italy. The Turkish market, as one of the E7-countries, is growing very quickly" says Peter Rothschild, President BioGaia AB.

"Given that there are approximately 300 probiotics marketed in Italy, the fact that we have been able to make such a significant penetration of the market in less than two years of marketing, speaks highly both of the quality of BioGaia's products, as well as Italchimici's know-how in the specific therapeutic area. We are very confident of continuing this success, both in Italy and in Turkey" says Bill Garrow, Managing Director, Italchimici SpA.

Latest press releases from BioGaia:

2007-09-20	BioGaia signs agreement for probiotic oral health products in Scandinavia
2007-09-06	BioGaia signs agreement in South America
2007-08-23	Interim report 1 January – 30 June 2007

For additional information contact:

Peter Rothschild, President, telephone: +46 8 - 555 293 00,
Jan Annwall, Executive vice President, telephone: +46 8 - 555 293 00

BioGaia is a biotechnology company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* (Reuteri), which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Small Cap list of the Nordic Stock Exchange in Stockholm.

www.biogaia.com